FDA approves UCB drug for treating epileptic seizures

The FDA today approved a drug from Belgium's UCB as an add-on therapy to treat partial seizures caused by epilepsy. The drug, branded Briviact, has also been recommended for approval in Europe. The FDA pointed out that people with epilepsy can have different responses to available treatments so it is important to have more options. Release | More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.